Last reviewed · How we verify
NCT03356535
Metabolic Signature of Healthy Lifestyle and HCC
trial in Hepatocellular Carcinoma in 294 participants. Completed in 15 September 2017.
15 September 2017
Quick facts
| Lead sponsor | International Agency for Research on Cancer |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 294 |
| Start date | 1 August 2015 |
| Primary completion | 15 September 2017 |
| Estimated completion | 15 September 2017 |
Conditions studied
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Sponsor
International Agency for Research on Cancer
Who can join
Adults 30 to 70, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and its incidence is increasing including in regions where hepatitis infection rates are low. This trend may be the result of increases in 'unhealthy lifestyle' factors. The main aim of this study is to identify metabolic signatures associated with healthy lifestyle behaviours and to relate these signatures to risk of developing HCC to investigate whether the metabolites were of predictive utility for HCC beyond data procured from questionnaires. To address this question, we exploited data from a large European cohort (EPIC) which includes detailed questionnaire-based data as well as metabolomic data.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Metabolic signature of healthy lifestyle and its relation with risk of hepatocellular carcinoma in a large European cohort.
Assi N, Gunter MJ, Thomas DC, Leitzmann M, et al · · 2018 · cited 27× · PMID 29924298 · DOI 10.1093/ajcn/nqy074
Verify or expand the search:
- PubMed search for NCT03356535
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
- NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
- NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
Other International Agency for Research on Cancer trials
Trials by the same sponsor.
- NCT07256912 — A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared t · Phase 4 · not yet recruiting
- NCT07193030 — Peer-Led Intervention To Reduce Alcohol Binge Drinking Among University Students In Romania · NA · not yet recruiting
- NCT05286034 — Using Artificial Intelligence-based ChatBot to Improve Women's Participation to Cervical Cancer Screening Programme · NA · recruiting
- NCT06749847 — HPV Self-sampling in the General Population · NA · recruiting
- NCT07407153 — Triaging of Women Detected With a Breast Lump on Clinical Breast Examination Using Portable Ultrasound Device · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03356535 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by International Agency for Research on Cancer
- Last refreshed: 29 November 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03356535.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing